Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma
| Autor: | Connors, Joseph M, Jurczak, Wojciech, Straus, David J, Ansell, Stephen M, Kim, Won S, Gallamini, Andrea, Younes, Anas, Alekseev, Sergey, Illés, Árpád, Picardi, Marco, Lech-Maranda, Ewa, Oki, Yasuhiro, Feldman, Tatyana, Smolewski, Piotr, Savage, Kerry J, Bartlett, Nancy L, Walewski, Jan, Chen, Robert, Ramchandren, Radhakrishnan, Zinzani, Pier L, Cunningham, David, Rosta, Andras, Josephson, Neil C, Song, Eric, Sachs, Jessica, Liu, Rachael, Jolin, Hina A, Huebner, Dirk, Radford, John, Luminari, Stefano |
|---|---|
| Přispěvatelé: | DIPARTIMENTO DI MEDICINA SPECIALISTICA, DIAGNOSTICA E SPERIMENTALE, Connors, J. M., Jurczak, W., Straus, D. J., Ansell, S. M., Kim, W. S., Gallamini, A., Younes, A., Alekseev, S., Illés, A., Picardi, M., Lech-Maranda, E., Oki, Y., Feldman, T., Smolewski, P., Savage, K. J., Bartlett, N. L., Walewski, J., Chen, R., Ramchandren, R., Zinzani, P. L., Cunningham, D., Rosta, A., Josephson, N. C., Song, E., Sachs, J., Liu, R., Jolin, H. A., Huebner, D., Radford, J. |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Male
Oncology medicine.medical_treatment chemistry.chemical_compound Immunologic Factor 0302 clinical medicine Brentuximab vedotin anti-CD30 Brentuximab vedotin Aged 80 and over Medicine (all) Orvostudományok General Medicine Middle Aged Hodgkin Disease Vinblastine Dacarbazine Survival Rate 030220 oncology & carcinogenesis Female Human medicine.drug Adult medicine.medical_specialty Neutropenia Adolescent Klinikai orvostudományok Bleomycin Disease-Free Survival Article Follow-Up Studie Young Adult 03 medical and health sciences Internal medicine medicine anti-CD30 Survival rate Aged Neoplasm Staging Chemotherapy Antineoplastic Combined Chemotherapy Protocol business.industry Hodgkin's lymphoma medicine.disease Immunoconjugate chemistry ABVD Doxorubicin business 030215 immunology |
| Popis: | none 29 si This article was published on December 10, 2017. All ECHELON-1 investigators are listed in the Supplementary Appendix, available at NEJM.org Background Brentuximab vedotin is an anti-CD30 antibody-drug conjugate that has been approved for relapsed and refractory Hodgkin's lymphoma. Methods We conducted an open-label, multicenter, randomized phase 3 trial involving patients with previously untreated stage III or IV classic Hodgkin's lymphoma, in which 664 were assigned to receive brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) and 670 were assigned to receive doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). The primary end point was modified progression-free survival (the time to progression, death, or noncomplete response and use of subsequent anticancer therapy) as adjudicated by an independent review committee. The key secondary end point was overall survival. Results At a median follow-up of 24.9 months, 2-year modified progression-free survival rates in the A+AVD and ABVD groups were 82.1% (95% confidence interval [CI], 78.7 to 85.0) and 77.2% (95% CI, 73.7 to 80.4), respectively, a difference of 4.9 percentage points (hazard ratio for an event of progression, death, or modified progression, 0.77; 95% CI, 0.60 to 0.98; P=0.03). There were 28 deaths with A+AVD and 39 with ABVD (hazard ratio for interim overall survival, 0.72 [95% CI, 0.44 to 1.17]; P=0.19). All secondary efficacy end points trended in favor of A+AVD. Neutropenia occurred in 58% of the patients receiving A+AVD and in 45% of those receiving ABVD; in the A+AVD group, the rate of febrile neutropenia was lower among the 83 patients who received primary prophylaxis with granulocyte colony-stimulating factor than among those who did not (11% vs. 21%). Peripheral neuropathy occurred in 67% of patients in the A+AVD group and in 43% of patients in the ABVD group; 67% of patients in the A+AVD group who had peripheral neuropathy had resolution or improvement at the last follow-up visit. Pulmonary toxicity of grade 3 or higher was reported in less than 1% of patients receiving A+AVD and in 3% of those receiving ABVD. Among the deaths that occurred during treatment, 7 of 9 in the A+AVD group were associated with neutropenia and 11 of 13 in the ABVD group were associated with pulmonary-related toxicity. Conclusions A+AVD had superior efficacy to ABVD in the treatment of patients with advanced-stage Hodgkin's lymphoma, with a 4.9 percentage-point lower combined risk of progression, death, or noncomplete response and of subsequent anticancer therapy at 2 years. (Funded by Millennium Pharmaceuticals and Seattle Genetics; ECHELON-1 ClinicalTrials.gov number, NCT01712490 ; EudraCT number, 2011-005450-60 .). mixed Joseph M. Connors; Wojciech Jurczak; David J. Straus; Stephen M. Ansell; Won S. Kim; Andrea Gallamini; Anas Younes; Sergey Alekseev; Árpád Illés; Marco Picardi; Ewa Lech-Maranda; Yasuhiro Oki; Tatyana Feldman; Piotr Smolewski; Kerry J. Savage; Nancy L. Bartlett; Jan Walewski; Robert Chen; Radhakrishnan Ramchandren; Pier L. Zinzani; David Cunningham; Andras Rosta; Neil C. Josephson; Eric Song; Jessica Sachs; Rachael Liu; Hina A. Jolin; Dirk Huebner; John Radford for the ECHELON-1 Study Group Joseph M. Connors; Wojciech Jurczak; David J. Straus; Stephen M. Ansell; Won S. Kim; Andrea Gallamini; Anas Younes; Sergey Alekseev; Árpád Illés; Marco Picardi; Ewa Lech-Maranda; Yasuhiro Oki; Tatyana Feldman; Piotr Smolewski; Kerry J. Savage; Nancy L. Bartlett; Jan Walewski; Robert Chen; Radhakrishnan Ramchandren; Pier L. Zinzani; David Cunningham; Andras Rosta; Neil C. Josephson; Eric Song; Jessica Sachs; Rachael Liu; Hina A. Jolin; Dirk Huebner; John Radford for the ECHELON-1 Study Group |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|